Over the past 18 months, Colcemid (Demecolcine) Solution industry trends have pivoted toward single-use, GMP-compliant formats after Thermo Fisher’s January 2024 launch of a sterile, endotoxin-tested 10 mL ampoule that cuts karyotyping prep time by 30%. The move triggered a ripple of strategic alliances: Oxford BioMedica partnered with Catalent to integrate the new solution into scaled-up viral-vector QC workflows, while South Korea’s GC Biopharma signed a March 2024 supply MoU with domestic CDMO ST Pharm to localize fill-finish and shorten APAC lead times by five weeks. Regulatory momentum followed: FDA’s updated <sup>14</sup>C labelling guidance (effective Q2 2024) now exempts sub-microgram cytostatic reagents from radio-tracking, removing a compliance barrier and spurring a 12% uptick in U.S. CRO orders. Investment activity intensified when Novo Holdings led a €35 M Series B in Dutch biotech Nucleus Biologics, earmarking half for a demecolcine-based cell-cycle synchronization platform. Finally, Thermo completed a tuck-in acquisition of Finnish reagent maker BioReplies in October 2023, securing proprietary low-DMSO formulation IP and doubling its biobank capacity for high-throughput cytogenetics screens.
